Hotspot activating mutations of the telomerase reverse transcriptase (hTERT) promoter region were recently described in several tumor types. These mutations lead to enhanced expression of telomerase, being responsible for telomere maintenance and allowing continuous cell division. Additionally, there are alternative telomere maintenance mechanisms, associated with histone H3 mutations, responsible for disrupting the histone code and affecting the regulation of transcription. Here, we investigated the clinical relevance of these mechanistically related molecules in medulloblastoma. Sixty-nine medulloblastomas, formalin fixed and paraffin embedded, from a cohort of patients aged 1.5-70 years, were used to investigate the hotspot mutations of the hTERT promoter region, i.e. H3F3A and HIST1H3B, using Sanger sequencing. We successfully sequenced hTERT in all 69 medulloblastoma samples and identified a total of 19 mutated cases (27.5%). c.-124:G>A and c.-146:G>A mutations were detected, respectively, in 16 and 3 samples. Similar to previous reports, hTERT mutations were more frequent in older patients (p < 0.0001), being found only in 5 patients <20 years of age. In addition, hTERT- mutated tumors were more frequently recurrent (p = 0.026) and hTERT mutations were significantly enriched in tumors located in the right cerebellar hemisphere (p = 0.039). No mutations were found on the H3F3A or HIST1H3B genes. hTERT promoter mutations are frequent in medulloblastoma and are associated with older patients, prone to recurrence and located in the right cerebellar hemisphere. On the other hand, histone 3 mutations do not seem to be present in medulloblastoma.

Keywords:
hTERT, Mutations, Medulloblastoma, Biomarkers
1.
Bryan TM, Cech TR: Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 1999;11:318-324.
2.
Cong YS, Wright WE, Shay JW: Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66:407-425.
3.
Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997;17:498-502.
4.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
5.
Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW: Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-179.
6.
Ozturk S, Sozen B, Demir N: Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species. Mol Hum Reprod 2014;20:15-30.
7.
Blasco MA, Hahn WC: Evolving views of telomerase and cancer. Trends Cell Biol 2003;13:289-294.
8.
Ding D, Zhou J, Wang M, Cong YS: Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. FEBS J 2013;280:3205-3211.
9.
Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
10.
Remke M, Ramaswamy V, Peacock J, et al: TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013;126:917-929.
11.
Killela PJ, Reitman ZJ, Jiao Y, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021-6026.
12.
Vinagre J, Almeida A, Pópulo H, et al: Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4:2185.
13.
Horn S, Figl A, Rachakonda PS, et al: TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-961.
14.
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-959.
15.
Bell RJ, Rube HT, Kreig A, et al: The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015;348:1036-1039.
16.
Rachakonda PS, Hosen I, de Verdier PJ, et al: TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 2013;110:17426-17431.
17.
Heaphy CM, de Wilde RF, Jiao Y, et al: Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333:425.
18.
Schwartzentruber J, Korshunov A, Liu XY, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482:226-231.
19.
Wu G, Broniscer A, McEachron TA, et al: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012;44:251-253.
20.
Huether R, Dong L, Chen X, et al: The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014;5:3630.
21.
Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM: Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 2009;55:53-62.
22.
Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013;12:1637-1638.
23.
Campanella NC, Celestino R, Pestana A, et al: Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet 2015;23:877-879.
24.
Batista R, Cruvinel-Carloni A, Vinagre J, et al: The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. Int J Cancer 2016;139:414-423.
25.
Huang DS, Wang Z, He XJ, et al: Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 2015;51:969-976.
26.
Koelsche C, Sahm F, Capper D, et al: Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013;126:907-915.
27.
Riffaud L, Hénaux PL: Prognostic factors of adult medulloblastomas: a review of the literature and perspectives. Neurochirurgie 2016;62:46-52.
28.
Shih DJ, Northcott PA, Remke M, et al: Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014;32:886-896.
29.
Northcott PA, Shih DJ, Remke M, et al: Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012;123:615-626.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.